Effectiveness against symptomatic COVID-19 was 75% in previously infected participants and 31% among those never infected.
Trial: Alternative COVID vaccine 75% cross-protective against symptomatic cases in previously infected
More from COVID-19More posts in COVID-19 »
- Data suggest SARS-CoV-2 could jump from raccoon dogs to people, but species barrier may interfere
- Quick takes: Moderna’s RSV vaccine, flu-COVID combo vaccines, new polio cases
- Study: US children at times received ineffective COVID-19 treatments
- NIH announces long-COVID trials to examine treatments for sleep, exercise disruptions